Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8221710 | 0.79 | L3MBTL1 (0.39) | HDAC6KDM4EALDH1A1MAPTIKBKE | |
| SCHEMBL14561832 | 0.78 | PIK3CA (0.36) | PIK3CAKDM4EALDH1A1LMNAMAPT | |
| SCHEMBL8226457 | 0.75 | HDAC6 (0.37) | HDAC6LMNAMAPTIKBKETBK1 | |
| SCHEMBL8226679 | 0.75 | GAA (0.40) | HDAC6KDM4EALDH1A1LMNAMAPT | |
| SCHEMBL8226625 | 0.75 | HDAC6 (0.33) | HDAC6KDM4EMAPTIKBKETBK1 | |
| SCHEMBL8229187 | 0.74 | HDAC6 (0.36) | HDAC6KDM4EMAPTIKBKETBK1 | |
| SCHEMBL8226646 | 0.73 | HDAC6 (0.40) | HDAC6KDM4EALDH1A1IKBKETBK1 | |
| SCHEMBL8226718 | 0.73 | CHRNB2 (0.35) | HDAC6MAPTIKBKETBK1RAB9A | |
| SCHEMBL8221284 | 0.73 | HDAC6 (0.36) | HDAC6LMNAIKBKETBK1EIF4A3 | |
| SCHEMBL8221308 | 0.72 | L3MBTL1 (0.39) | HDAC6KDM4EALDH1A1MAPTIKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465740-B2 | 2-heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | MERCK SHARP & DOHME LLC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066620-A1 | 2-Heteroaryl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | PIK3CA 1599/4885HDAC6 1326/4885KDM4E 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.